KRRO

Over the past six months (April 2026 - October 2026), Korro Bio experienced several stock-related events. On October 5, 2026, the first cohort of healthy volunteers was dosed in the Phase 1/2 clinical trial (ANCHOR) for KRRO-121. Inducement grants under Nasdaq Listing Rule 5635(c)(4) were reported on September 11, 2026, and August 14, 2026. The company announced its participation in upcoming investor conferences on August 27, 2026. On August 6, 2026, Korro reported its Second Quarter 2026 financial results, highlighting a cash runway into the second half of 2028, a pause in collaboration revenue from Novo Nordisk, decreased R&D and G&A expenses, and a narrowed net loss, while also receiving Orphan Drug Designation from the EMA for KRRO-121 and nominating KRRO-111 as a development candidate. Earlier, on May 7, 2026, First Quarter 2026 financial results showed $157.1 million in cash and marketable securities after an oversubscribed $85 million private placement, extending its cash runway into the second half of 2028, with a regulatory filing for KRRO-121 expected in H2 2026 and its GalNAc AATD program achieving over 90% in vivo RNA editing, with a development candidate expected in Q2 2026. The stock price experienced a significant decline of 70.71% over the year leading up to September 18, 2026, with a 52-week trading range between $5.20 and $55.89.